Tesamorelin cycle length: how long should a course run?

Last updated 2026-07-25

What does tesamorelin's approval actually cover, and does it include a cycle length?

Tesamorelin is FDA-approved under the brand name Egrifta (and its follow-on formulation Egrifta SV) for one specific indication: reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy ^[1]. The approval is based on continuous daily subcutaneous dosing, evaluated in phase 3 trials that ran 26 weeks, with an extension phase out to 52 weeks ^[2]. There is no FDA-sanctioned "cycle" in the bodybuilding sense of a defined on-period followed by a defined off-period. The drug label and the trial protocols behind it describe continuous use for as long as the treatment goal (visceral fat reduction) is being maintained and tolerated. If you're seeing recommendations for 12-week cycles, 8-week cycles, or specific rest intervals, those come from off-label practice patterns and compounding pharmacy protocols, not from the trial evidence ^{[2] [3]}. This matters for how you read everything else in this article. Below, the timelines are drawn from actual trial durations. Anything about "cycling on and off" beyond that is inference, and honest sources should say so plainly.

How long did the key tesamorelin trials actually run?

The two key phase 3 trials that supported approval were 26-week, multicenter, double-blind, placebo-controlled studies, pooled for the primary analysis, with a safety extension phase collecting additional data ^[3]. Patients who completed the initial 26 weeks could continue into extension periods. Pooled safety and efficacy data have been reported out to roughly 52 weeks ^[2]. A 2010 pooled analysis in the Journal of Clinical Endocrinology and Metabolism described the trial design and reported that visceral adipose tissue reductions achieved during the initial period were generally maintained through the extension, while patients switched from tesamorelin to placebo saw fat regain ^[3]. This is the core data point people mean when they ask "how long is a cycle": the trials that got tesamorelin approved ran continuously for 6 months to a year, not in short pulsed blocks. More recent work has continued to study tesamorelin in HIV populations on modern antiretroviral regimens. A 2024 study in AIDS examined efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, a drug class that wasn't the backbone therapy in the original 2010 trials ^[4]. This kind of follow-up work matters because antiretroviral regimens have changed a lot since the original approval studies, and confirming the drug still performs similarly under current standard-of-care HIV treatment is not a given.

What happens to visceral fat if you stop tesamorelin?

Fat regain after discontinuation is one of the best-documented findings in the tesamorelin literature, and it directly shapes any cycling decision. In the pooled phase 3 analysis, patients who were switched from tesamorelin to placebo during the extension phase lost the visceral fat benefit, with regain trending back toward baseline over the following weeks to months ^[3]. This is consistent with the underlying mechanism. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue. It works by stimulating the pituitary to release more of the body's own growth hormone, which in turn drives lipolysis in visceral fat depots ^{[2] [5]}. It does not permanently reprogram fat storage. Once you remove the stimulus, GH pulsatility drops back toward your baseline, and visceral fat tends to reaccumulate. A 2021 study in AIDS looked specifically at fat quality (more than quantity), finding that tesamorelin improved measures of visceral fat quality independent of the raw volume changes ^[6]. Whether those quality improvements persist after stopping treatment wasn't the focus of that paper, and it's a real gap: most of what we know about durability comes from on-drug maintenance data, not long post-discontinuation follow-up. Practically, this means the "cycle off" period that some off-label protocols recommend is working against the drug's known mechanism. If visceral fat reduction is the goal, stopping for weeks at a time predictably erodes progress based on the trial extension data ^[3].

Is there any trial evidence for short or intermittent tesamorelin cycles?

No. Every phase 3 trial and every major follow-up study cited in the FDA approval package and subsequent literature used continuous daily dosing for extended periods (26 to 52 weeks), not intermittent pulsed cycles ^{[2] [3]}. There is no published randomized controlled trial testing a defined "12 weeks on, 4 weeks off" schedule or similar cycling pattern for tesamorelin. A 2026 meta-analysis in Obesity Research & Clinical Practice pooled randomized controlled trial data on tesamorelin's body composition, hepatic fat, and metabolic and safety outcomes in HIV-associated lipodystrophy ^[7]. That analysis, like its source trials, is built entirely on continuous-dosing study arms. If a cycling protocol had superior or even equivalent efficacy to continuous dosing, it would show up in this kind of pooled analysis; it doesn't, because nobody has run that trial. This is worth saying directly: recommendations for specific cycle lengths that circulate outside clinical literature are not backed by controlled data. They may be reasonable clinical judgment applied by a prescriber managing cost, tolerability, or an off-label use case, but they are not validated protocols in the way the 26-week and 52-week continuous regimens are.

What did the phase 3 trials show at 26 weeks versus 52 weeks?

The comparison below summarizes what the pooled phase 3 analysis and extension data reported, to give a concrete sense of what "cycle length" actually correlated with in the real trials ^[3]. | Trial phase | Duration | Reported outcome pattern |

Does tesamorelin need a PCT (post-cycle therapy) like anabolic compounds do?

No, and treating tesamorelin like an anabolic steroid protocol is a category error. Tesamorelin doesn't suppress your own hormone axis the way exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. It stimulates your pituitary's own GHRH receptors to release more growth hormone; it doesn't shut down an endogenous system that then needs to be restarted ^{[2] [5]}. What actually happens on discontinuation is simpler and less dramatic: GH pulsatility and IGF-1 levels tend to drift back toward your pre-treatment baseline over time, and the downstream visceral fat benefit fades along with it, based on the placebo-switch data from the phase 3 extension ^[3]. There's no described withdrawal syndrome, and no clinical literature calling for a specific post-cycle recovery protocol. If you're coming from an anabolic steroid or SARMs background and looking for the tesamorelin equivalent of a PCT, the honest answer is that the concept doesn't map. What you actually need to plan for is the fat regain pattern described above, not a hormonal rebound.

How does half-life and dosing frequency relate to cycle length?

Cycle length (how many weeks or months you run the drug) is a different question from dosing frequency (how often you inject within a day), but people often conflate them. A 2015 population pharmacokinetic analysis in Clinical Pharmacokinetics modeled tesamorelin's pharmacokinetics across HIV-infected patients and healthy subjects, characterizing absorption and elimination parameters that inform the once-daily dosing schedule used in the approved label ^[9]. Because tesamorelin has a short circulating half-life, it's dosed once daily by subcutaneous injection, not weekly or monthly like some longer-acting peptides. That daily dosing requirement is separate from the question of total treatment duration. You can be on a correctly dosed daily regimen for a 6-week off-label trial or for the 52-week extension studied in the key trials; the daily injection schedule doesn't change, only the total number of weeks does. For the mechanics of daily dosing itself, including timing relative to meals and sleep, see best time to take tesamorelin peptide. For the injection technique and rotation across sites over a multi-week course, see tesamorelin how to inject and tesamorelin injection sites. And for the pharmacokinetic detail behind why daily dosing was chosen, see tesamorelin half life.

What about tesamorelin cycles for non-HIV, off-label uses like general fat loss or anti-aging?

This is where the evidence base thins out fast, and it's important to be blunt about it. Tesamorelin's FDA approval is specifically for visceral fat reduction in HIV-associated lipodystrophy ^[1]. Off-label use for general fat loss, body recomposition, or anti-aging in people without HIV lipodystrophy has not been tested in the phase 3 trial framework at all. A 2013 review on growth hormone in the aging male discusses GH physiology and age-related decline in GH secretion broadly ^[10], but that is a review of GH biology generally, not a tesamorelin-specific cycling trial in aging non-HIV populations. Extrapolating the HIV lipodystrophy trial durations (26 to 52 weeks continuous) to a healthy or aging population chasing general fat loss is exactly that: extrapolation, not evidence. A 2026 review in the International Journal of Molecular Sciences on therapeutic peptides in aesthetic, metabolic, and endocrine conditions covers tesamorelin among other peptides used in these broader contexts ^[11], and separate orthopaedic and sports medicine literature has started cataloguing peptide use patterns among physicians treating musculoskeletal and performance-related concerns ^[12] . These reviews describe use patterns and mechanisms; they are not the same as controlled trial evidence for a specific off-label cycle length, and none of them establish an evidence-based cycling protocol outside the approved indication. If you're considering tesamorelin outside the HIV lipodystrophy indication, that's a conversation to have with a prescriber who can weigh the off-label evidence gap honestly, not a decision to make from a forum-sourced cycle schedule.

What monitoring should happen during a tesamorelin course, and does that change with cycle length?

Regardless of how long you run tesamorelin, the monitoring needs described in the clinical literature center on a few consistent things: IGF-1 levels (as a marker of GH axis activation), glucose metabolism, and injection site reactions ^{[2] [3]}. A 2019 randomized, double-blind, multicenter trial in The Lancet HIV specifically studied tesamorelin's effects on non-alcoholic fatty liver disease in HIV, tracking liver-related outcomes alongside standard metabolic monitoring ^[13]. A 2017 study in AIDS reported that visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients ^[14], and a 2011 study in the same journal looked at inflammatory markers in relation to visceral fat reduction on tesamorelin . These metabolic and inflammatory readouts were tracked across the full trial durations (26 to 52 weeks), more than at a single cycle endpoint, which argues for ongoing monitoring throughout a course rather than only at the start and end. Longer courses don't inherently need different monitoring categories, but they do mean more monitoring timepoints. A prescriber running a patient through 52 weeks should be checking in more times than one running a 12-week trial, simply because there's more calendar time in which something could shift.

What's a reasonable, evidence-grounded way to think about cycle length in practice?

Start from what the trials actually did: continuous daily dosing for 26 weeks as the primary evaluation window, with extension data supporting continuation to 52 weeks and beyond for maintained benefit ^{[2] [3]}. If your goal matches the approved indication (visceral fat reduction in HIV lipodystrophy), that continuous, extended framework is the only one with real trial support behind it. If you stop, expect the visceral fat benefit to erode over subsequent weeks to months, based on the placebo-switch arm data ^[3]. That's not a guess; it's what happened to the patients in the extension phase who were taken off active drug. Plan for that regain pattern rather than being surprised by it. For anything outside the approved indication, the honest position is that nobody has run the trial that would tell you the optimal cycle length. A 2011 review in Drugs on tesamorelin's use in HIV-associated lipodystrophy ^[15] and a 2012 review in The Annals of Pharmacotherapy covering the same territory ^[16] both frame the evidence base around the approved use case; neither establishes a validated off-label cycling schedule. Cost is a legitimate part of this decision too, since 26-to-52-week continuous courses are a real financial commitment. See tesamorelin cost for what that actually runs. And however long a course you're considering, reconstitution technique matters just as much on day 300 as it does on day 1: see how to reconstitute tesamorelin. At Tesamorelin Co, our own position mirrors what the trial data supports: treat tesamorelin as a continuous-course therapy tied to a monitored, provider-reviewed protocol, not a cycled compound borrowed from anabolic steroid practice.

Where should you go for a monitored, provider-reviewed tesamorelin protocol?

Given the fat-regain-on-discontinuation pattern documented in the phase 3 extension data ^[3], and the total absence of controlled trial evidence for intermittent cycling, the safest path is a protocol built around continuous dosing under a prescriber who can order IGF-1 and metabolic monitoring at sensible intervals. Tesamorelin Co works with a provider-reviewed pathway and names its fulfilling pharmacy partner directly so you know exactly who is compounding and dispensing your prescription, rather than piecing together a course from unverified sources. That's especially relevant given how compounded tesamorelin is regulated: bulk tesamorelin acetate sourcing for compounding falls under FDA's 503A and 503B bulk drug substance frameworks ^{[17] [18] [19]}, and pharmacy compounding itself is governed by 21 U.S.C. 353a . A provider-reviewed route means someone is actually checking that the source, the dose, and the duration match what's defensible, rather than you guessing at a cycle length pulled from an unverified forum post.

Frequently asked questions

How long is a typical tesamorelin cycle?

There's no single "typical" cycle in the approved sense. The key phase 3 trials used continuous daily dosing for 26 weeks, with extension data out to 52 weeks ^[10]. Off-label protocols sometimes describe shorter blocks (8 to 12 weeks), but those aren't backed by controlled trial data; they're clinical practice patterns, not tested regimens.

Can you take tesamorelin continuously for a year or longer?

The phase 3 extension data covers continuous use out to about 52 weeks, with visceral fat reduction generally maintained on active drug during that period ^[10]. Data on use beyond a year in the original trial framework is limited, so anything past 52 weeks continuous is less directly supported by the original approval studies.

What happens if you stop tesamorelin after a few months?

In the phase 3 extension, patients switched from tesamorelin to placebo showed a trend toward visceral fat regain over the following weeks to months ^[10]. This tracks with the drug's mechanism: it stimulates GH release rather than permanently altering fat storage, so removing the stimulus lets fat drift back toward baseline.

Do you need a break between tesamorelin cycles, like a PCT?

No formal break or post-cycle therapy is described in the tesamorelin literature. Unlike anabolic steroids, tesamorelin doesn't suppress an endogenous axis that needs restarting; it stimulates your own GHRH receptors ^[3][4]. The real consideration on stopping is fat regain, not hormonal withdrawal.

Is there an FDA-approved cycle length for tesamorelin?

The FDA approval for Egrifta/Egrifta SV is based on continuous daily dosing evaluated over 26 weeks initially, with extension safety and efficacy data to 52 weeks ^[2][10]. There's no approved "cycle" with a defined on/off schedule; the approved use model is ongoing therapy for as long as the visceral fat benefit is desired and tolerated.

Does tesamorelin cycle length differ for HIV lipodystrophy versus off-label fat loss use?

The only cycle-length data that exists comes from HIV lipodystrophy trials (26 to 52 weeks continuous) ^[10]. There is no equivalent controlled trial data for off-label general fat loss or anti-aging use in non-HIV populations, so any cycle length used there is extrapolated, not evidence-based.

How often do you inject tesamorelin during a cycle?

Tesamorelin is dosed once daily by subcutaneous injection throughout a course, based on the pharmacokinetic profile characterized in population PK modeling ^[19]. This daily frequency stays constant regardless of whether the total course is 12 weeks or a full year; only the total duration changes, not the injection schedule.

Will visceral fat come back after finishing a tesamorelin cycle?

Trial data suggests yes, at least based on the placebo-switch arm of the phase 3 extension, where patients taken off tesamorelin trended back toward baseline visceral fat over subsequent weeks to months ^[10]. There's no published long-term post-discontinuation follow-up establishing how long any residual benefit lasts.

Can you repeat multiple tesamorelin cycles over several years?

This hasn't been studied in a controlled trial format. The key trial data covers continuous use to about 52 weeks ^[10]; repeated cycling over multiple years with defined breaks in between is an off-label practice pattern without dedicated trial evidence behind it.

Does tesamorelin cycle length affect liver fat or liver enzyme outcomes?

A 2019 randomized trial in The Lancet HIV studied tesamorelin's effect on non-alcoholic fatty liver disease over its trial duration ^[20], and a 2017 AIDS study linked visceral fat reduction to improved liver enzymes ^[18]. Both were measured across continuous dosing periods, not intermittent cycles, so cycle-specific liver effects aren't separately established.

Is tesamorelin safe to use for multiple consecutive years without stopping?

Long-term safety data on continuous use beyond the roughly 52-week extension studied in the phase 3 program is limited ^[10]. A 2026 meta-analysis pooled randomized trial safety outcomes for tesamorelin in HIV-associated lipodystrophy ^[17], but multi-year uninterrupted use hasn't been the subject of a dedicated long-term trial.

Do integrase inhibitor regimens change how long a tesamorelin course should run?

A 2024 study in AIDS specifically evaluated tesamorelin's efficacy and safety in people with HIV on integrase inhibitor-based regimens ^[6], reflecting how antiretroviral therapy has evolved since the original approval trials. It didn't establish a different cycle length; it confirmed the drug's performance profile under current standard HIV treatment.

Sources

1. Drugs@FDA, FDA-approved drug products database: Tesamorelin is FDA-approved (as Egrifta/Egrifta SV) specifically for reduction of excess visceral adipose tissue in HIV-infected patients with lipodystrophy
2. Tesamorelin, Nature Reviews Drug Discovery, 2011 (PMID 21283099): Describes tesamorelin's development and the trial framework of continuous dosing supporting approval, with extension data to 52 weeks
3. Tesamorelin, PubMed PMID 31644039, 2012: Confirms tesamorelin's mechanism as a GHRH analogue driving GH-mediated lipolysis in visceral fat depots
4. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, AIDS, 2024 (PMID 38905488): Evaluated tesamorelin efficacy and safety specifically in patients on integrase inhibitor-based antiretroviral regimens
5. FDA, bulk drug substances used in compounding under section 503A: Describes the FDA framework governing bulk drug substances, including tesamorelin acetate, used in 503A pharmacy compounding
6. 21 CFR 216.24, the 503B Bulks List: Sets out the bulk drug substances list applicable to 503B outsourcing facility compounding
7. 21 CFR 216.23, the final 503A Bulks List: Sets out the bulk drug substances list applicable to 503A pharmacy compounding
8. Effects of tesamorelin (TH9507) in HIV-infected patients with excess abdominal fat: pooled phase 3 analysis, J Clin Endocrinol Metab, 2010 (PMID 20554713): Phase 3 trials ran 26 weeks with extension to 52 weeks; visceral fat reduction was maintained on continued tesamorelin and patients switched to placebo showed fat regain
9. Tesamorelin: a review of its use in HIV-associated lipodystrophy, Drugs, 2011 (PMID 21668043): Reviews tesamorelin's evidence base and clinical use framework in HIV-associated lipodystrophy
10. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy, Annals of Pharmacotherapy, 2012 (PMID 22298602): Reviews tesamorelin's pharmacology and approved use case in HIV-associated lipodystrophy
11. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions, International Journal of Molecular Sciences, 2026 (PMID 42123471): Reviews tesamorelin among other peptides used in broader aesthetic and metabolic contexts outside the core HIV indication
12. Tesamorelin improves fat quality independent of changes in fat quantity, AIDS, 2021 (PMID 33756511): Found tesamorelin improved visceral fat quality measures independent of raw fat volume changes
13. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin: meta-analysis of RCTs, Obesity Research & Clinical Practice, 2026 (PMID 41545261): Meta-analysis pooling randomized controlled trial data on tesamorelin, all built on continuous-dosing study arms
14. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV, AIDS, 2017 (PMID 28832410): Reported that visceral fat reduction with tesamorelin was associated with improved liver enzymes in HIV patients
15. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects, Clinical Pharmacokinetics, 2015 (PMID 25358450): Modeled tesamorelin pharmacokinetics supporting the once-daily subcutaneous dosing schedule
16. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: randomised trial, The Lancet HIV, 2019 (PMID 31611038): Randomized double-blind multicenter trial studied tesamorelin's effect on NAFLD outcomes in HIV patients
17. Growth hormone in the aging male, Best Practice & Research Clinical Endocrinology & Metabolism, 2013 (PMID 24054930): Reviews GH physiology and age-related decline in GH secretion in aging males generally, not tesamorelin-specific cycling
18. Effect of tesamorelin with and without dorsocervical fat: post hoc phase III analysis, Journal of Clinical and Translational Science, 2023 (PMID 36845310): Post hoc subgroup analysis of phase 3 trial data by baseline dorsocervical fat status
19. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions, JAAOS Global Research & Reviews, 2026 (PMID 41490200): Catalogues peptide therapy use patterns, including tesamorelin, in orthopaedic clinical contexts
20. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians, American Journal of Sports Medicine, 2026 (PMID 41476424): Describes injectable peptide therapy use patterns among orthopaedic and sports medicine physicians
21. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat, AIDS, 2011 (PMID 21516030): Studied inflammatory marker changes in relation to visceral fat reduction on tesamorelin
22. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance, Sports Medicine, 2026 (PMID 41966639): Reviews safety and efficacy data for approved and unapproved peptide therapies including tesamorelin in athletic performance contexts
23. 21 U.S.C. 353a, pharmacy compounding: Establishes the federal statutory framework governing pharmacy compounding under section 503A